2011, Number 598
<< Back Next >>
Rev Med Cos Cen 2011; 68 (598)
Síndrome neuroléptico maligno
Cabezas SY
Language: Spanish
References: 10
Page: 381-383
PDF size: 197.61 Kb.
ABSTRACT
Neuroleptic Malignant Syndrome is the result of the use of neuroleptic drugs, which generate a metabolic disorder secondary to antagonism of dopamine receptors in the hypothalamus.
REFERENCES
Caroff SN. Mann SC. Neuroleptic malignat síndrome. Med. Clin N Am 1993,7 185-202.
Ferri: Practical Guide to the Care of the Medical Patient, 8th ed.; Chapter 3 - Diseases and Disorders
Goldman: Cecil Medicine, 23rd ed.; Chapter 460 - MEDICAL CONSULTA-TION IN PSYCHIATRY >> MEDICAL COMPLICATIONS OF PSYCHIATRIC TREATMENTS.
Hunford. William E. “Massachusetts General Hospital Anestesia”. Edición original. Editorial Marbon Libros S.A. 2005. Pag 291-292.
Jacobson: Psychiatric Secrets, 2nd ed.; Chapter 48 - ANTIPSYCHOTIC MEDICATIONS
Jacobson: Psychiatric Secrets, 2nd ed.; Chapter 77 - NEUROLEPTIC MALIG-NANT SYNDROME
Revista Médica de Chile, Santiago octubre 2005.
Shannon: Haddad and Winchester’s Clinical Management of Poisoning and Drug Overdose, 4th ed.; Chapter 10 - Clinical Neurotoxicology > ... > NEUROLEPTIC MALIGNANT SYNDROME
Stern: Massachusetts General Hospital Comprehensive Clinical Psychiatry, 1st ed.; CHAPTER 55 - Catatonia, Neuroleptic Malignant Syndrome, and Serotonin Syndrome.
Wikipedia (2010). Síndrome Neuroléptico Maligno. Obtenida el 10 marzo 2011, de http://es.wikipedia.org/wiki/Síndrome_neuroléptico_maligno.